UCLA Immunogenetics Center, Los Angeles, CA, USA.
Am J Transplant. 2010 Jan;10(1):26-9. doi: 10.1111/j.1600-6143.2009.02927.x. Epub 2009 Dec 2.
The ways we measure whether a patient is sensitized to HLA antigens and to what extent sensitization affects access to transplantation have changed remarkably during the past decade. What we mean by sensitized and broadly sensitized today is heavily dependent upon the sensitivity of the test that is used to measure antibodies. Because we provide additional allocation points for broadly sensitized patients in the United States kidney allocation system in an effort to compensate for their biological disadvantage, some consistency and accountability are required. The calculated panel-reactive antibody, which provides an estimate of the percentage of deceased organ donors that will be crossmatch incompatible for a candidate provides both consistency and accountability.
在过去的十年中，我们衡量患者是否对 HLA 抗原敏感以及敏感程度如何影响移植机会的方法发生了显著变化。今天我们所说的敏感和广泛敏感在很大程度上取决于用于测量抗体的测试的灵敏度。由于我们在美国肾脏分配系统中为广泛敏感的患者提供额外的分配点，以努力弥补他们的生物学劣势，因此需要一定的一致性和问责制。计算出的面板反应性抗体提供了对候选者进行交叉匹配不相容的已故器官供体的百分比的估计，这既提供了一致性，也提供了问责制。
